Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.40 |
| ▸ | PREP | P48147 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | PDE8B | O95263 | 1/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2688839 | 1.00 | HSD17B10 (0.43) | HSD17B10HPGDEPHX1PREPSMN1; SMN2 | |
| SCHEMBL3612669 | 0.95 | HSD17B10 (0.47) | HSD17B10HPGDEPHX1SMN1; SMN2NPC1 | |
| SCHEMBL5848851 | 0.95 | HSD17B10 (0.47) | HSD17B10HPGDEPHX1SMN1; SMN2NPC1 | |
| SCHEMBL3592625 | 0.95 | HSD17B10 (0.47) | HSD17B10HPGDEPHX1SMN1; SMN2NPC1 | |
| SCHEMBL3604748 | 0.95 | HSD17B10 (0.47) | HSD17B10HPGDEPHX1SMN1; SMN2NPC1 | |
| SCHEMBL3612674 | 0.95 | HSD17B10 (0.47) | HSD17B10HPGDEPHX1SMN1; SMN2NPC1 | |
| SCHEMBL19958804 | 0.95 | HSD17B10 (0.47) | HSD17B10HPGDEPHX1SMN1; SMN2NPC1 | |
| SCHEMBL5940026 | 0.85 | HSD17B10 (0.44) | HSD17B10HPGDEPHX1PREPSMN1; SMN2 | |
| SCHEMBL5940033 | 0.85 | HSD17B10 (0.44) | HSD17B10HPGDEPHX1PREPSMN1; SMN2 | |
| SCHEMBL2896341 | 0.84 | HSD17B10 (0.45) | HSD17B10HPGDEPHX1PREPSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8168657-B2 | administering a solenopsin derivative such as 2-methyl-6-(2-phenylethyl)piperidine or other piperidine derivatives to treat a tumor or cancer in a patient | BOWEN J PHILLIP (US) | 2012-05-01 | — | — | US | disclosed |
| US-20050038071-A1 | Solenopsin a, b and analogs and as novel angiogenesis inhibitors | BOWEN J PHILLIP (US) | 2005-02-17 | — | — | US | disclosed |
| US-6369078-B1 | Solenopsin derivatives and analogues as fire ant suppressants | BOWEN J PHILLIP (US) | 2002-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050038071-A1 | Solenopsin a, b and analogs and as novel angiogenesis inhibitors | VEGFA, TEK, FLT1 | HSD17B10 140/4885HPGD 117/4885EPHX1 533/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.